导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.03% | 2952/4773 |
| 近一周 | -2.09% | 3370/5465 |
| 近一月 | -0.38% | 799/5421 |
| 近一季 | -0.50% | 1076/5231 |
| 近半年 | -8.80% | 3557/4920 |
| 近一年 | 3.49% | 2065/4394 |
| 近两年 | 38.19% | 1977/2954 |
| 近三年 | 28.97% | 1121/2253 |
| 成立以来 | 112.89% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
5.40% 395/4961 |
-12.44% 4403/5312 |
- - |
- - |
| 2025 | 15.95% 2500/4813 |
-1.10% 2579/3635 |
5.71% 552/4076 |
4.05% 3704/4524 |
6.59% 356/4813 |
| 2024 | 13.78% 1107/3463 |
6.26% 304/2808 |
1.38% 476/3014 |
7.65% 2807/3129 |
-1.89% 1878/3463 |
| 2023 | 12.69% 56/2656 |
7.02% 616/2280 |
0.07% 346/2385 |
5.44% 88/2515 |
-0.20% 190/2655 |
| 2022 | -4.42% 93/2207 |
1.78% 92/1919 |
-1.92% 1760/2016 |
-3.85% 44/2113 |
-0.41% 1602/2208 |
| 2021 | 23.73% 127/1822 |
7.12% 82/1255 |
0.35% 1104/1330 |
11.07% 114/1466 |
3.63% 411/1822 |
| 2020 | 9.48% 842/1250 |
-8.44% 611/1028 |
6.72% 855/1067 |
10.11% 588/1164 |
1.75% 1019/1184 |
| 2019 | 19.21% 677/1092 |
24.76% 493/754 |
-7.82% 573/804 |
-4.24% 763/850 |
8.25% 331/918 |
| 2018 | -20.85% 202/834 |
- - |
- - |
- - |
-7.99% 77/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝标普中国A股红利机会ETF联接A(LOF) VS. 长安沪深300非周期A(740101) |